StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) stock

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.45−0.03 (-5.40%)

Close on Nov 16, 2026Market cap $124.31MP/E –Yield –

Akebia Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Akebia Therapeutics's total assets was $349.66M at Jun 30, 2026. For fiscal 2025 it was $376.57M, up 70.6% from the year before. Over ten years it grew 10.2% a year on average. The highest annual figure on record is $996.54M in fiscal 2018.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$376.57M+70.6%
FY2024Dec 31, 2024$220.67M-8.7%
FY2023Dec 31, 2023$241.70M-32.1%
FY2022Dec 31, 2022$356.05M-32.7%
FY2021Dec 31, 2021$529.35M-17.8%
FY2020Dec 31, 2020$644.14M-16.5%
FY2019Dec 31, 2019$771.20M-22.6%
FY2018Dec 31, 2018$996.54M+173.6%
FY2017Dec 31, 2017$364.25M+21.3%
FY2016Dec 31, 2016$300.22M+110.0%
FY2015Dec 31, 2015$142.94M+28.8%
FY2014Dec 31, 2014$111.00M+220.2%
FY2013Dec 31, 2013$34.67M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$349.66M+1.2%
Q1 FY2026Mar 31, 2026$362.52M+16.9%
Q4 FY2025Dec 31, 2025$376.57M+70.6%
Q3 FY2025Sep 30, 2025$364.15M+75.8%
Q2 FY2025Jun 30, 2025$345.60M+56.9%
Q1 FY2025Mar 31, 2025$310.19M+37.6%
Q4 FY2024Dec 31, 2024$220.67M-8.7%
Q3 FY2024Sep 30, 2024$207.14M-11.9%
Q2 FY2024Jun 30, 2024$220.20M-13.2%
Q1 FY2024Mar 31, 2024$225.48M-19.7%
Q4 FY2023Dec 31, 2023$241.70M-32.1%
Q3 FY2023Sep 30, 2023$235.00M-47.1%
Q2 FY2023Jun 30, 2023$253.71M-52.1%
Q1 FY2023Mar 31, 2023$280.93M-48.1%
Q4 FY2022Dec 31, 2022$356.05M-32.7%
Q3 FY2022Sep 30, 2022$444.25M-26.2%
Q2 FY2022Jun 30, 2022$529.88M-13.4%
Q1 FY2022Mar 31, 2022$541.80M-13.8%
Q4 FY2021Dec 31, 2021$529.35M-17.8%
Q3 FY2021Sep 30, 2021$602.27M-10.9%
Q2 FY2021Jun 30, 2021$611.86M-17.9%
Q1 FY2021Mar 31, 2021$628.70M-20.2%
Q4 FY2020Dec 31, 2020$644.14M-16.5%
Q3 FY2020Sep 30, 2020$676.14M-15.0%
Q2 FY2020Jun 30, 2020$745.17M-9.5%
Q1 FY2020Mar 31, 2020$787.72M-11.6%
Q4 FY2019Dec 31, 2019$771.20M-22.6%
Q3 FY2019Sep 30, 2019$795.22M+96.9%
Q2 FY2019Jun 30, 2019$823.53M+99.0%
Q1 FY2019Mar 31, 2019$890.79M+101.2%
Q4 FY2018Dec 31, 2018$996.54M+173.6%
Q3 FY2018Sep 30, 2018$403.83M+19.3%
Q2 FY2018Jun 30, 2018$413.78M+22.8%
Q1 FY2018Mar 31, 2018$442.71M+70.8%
Q4 FY2017Dec 31, 2017$364.25M+21.3%
Q3 FY2017Sep 30, 2017$338.59M+100.2%
Q2 FY2017Jun 30, 2017$336.82M–
Q1 FY2017Mar 31, 2017$259.26M–
Q4 FY2016Dec 31, 2016$300.22M–
Q3 FY2016Sep 30, 2016$169.12M–

More Akebia Therapeutics figures

See a number that looks wrong?